Dr Roy Baynes | Senior Vice President And Head Global Clinical Development, Chief Medical Officer
Merck Sharp and Dohme (MSD)

Dr Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)

Roy Baynes is Senior Vice President and Head, Global Clinical Development and Chief Medical Officer at Merck Sharp & Dohme (MSD). He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration.

He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.

Appearances:



Conference Day 1 - Tuesday 31st March 2020 @ 14:20

PD-1 antibodies are transforming cancer therapy both as mono- and in combination

  • PD-1 antibody activity in monotherapy may be enriched with precision medicine tools.
  • Precision medicine may help define resistance biology and enable rational combinations.
  • Certain combinations (e.g. chemotherapy or TKIs + PD-1 antibodies) may be broadly active without regard for biomarker-based selection.

Conference Day 1 - Tuesday 31st March 2020 @ 17:20

Panel discussion: Precision medicine for immunotherapy

  • Using biomarkers and diagnostics to start correlating success rates in immunotherapy: how to know when to apply these
  • Which is more important: stratification of patients using biomarkers or identifying the correct cells for a specific application?
  • Gene editing therapeutics
last published: 04/Jun/20 08:25 GMT

back to speakers